Send to

Choose Destination
Oncotarget. 2019 Feb 19;10(15):1507-1524. doi: 10.18632/oncotarget.26682. eCollection 2019 Feb 19.

TGF-β inducible epithelial-to-mesenchymal transition in renal cell carcinoma.

Author information

Martin Luther University Halle-Wittenberg, Institute for Medical Immunology, 06112 Halle, Germany.
State Hospital, Healthcare Centre Glantal, 55590 Meisenheim, Germany.


Epithelial-to-mesenchymal transition (EMT) is a crucial step in cancer progression and the number one reason for poor prognosis and worse overall survival of patients. Although this essential process has been widely studied in many solid tumors as e.g. melanoma and breast cancer, more detailed research in renal cell carcinoma (RCC) is required, especially for the major EMT-inducer transforming growth factor beta (TGF-β). Here, we provide a study of six different RCC cell lines of two different RCC subtypes and their response to recombinant TGF-β1 treatment. We established a model system shifting the cells to a mesenchymal cell type without losing their mesenchymal character even in the absence of the external stimulus. This model system forms a solid basis for future studies of the EMT process in RCCs to better understand the molecular basis of this process responsible for cancer progression.


Smad-signaling pathway; TGF-β; epithelial-to-mesenchymal transition; inhibition; renal cell carcinoma

Conflict of interest statement

CONFLICTS OF INTEREST All authors declare no conflict of interest.

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center